Mesenchymal Stromal Cells‐Mediated Tumor‐Targeted Delivery of Oncolytic Bacteria Combined With Immune Checkpoint Blockade Against Melanoma
- 1Clinical Stem Cell Center Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School Nanjing China
- 2Clinical Stem Cell Center Nanjing Drum Tower Hospital Nanjing University of Chinese Medicine Nanjing China
- 3Department of Laboratory Medicine Nanjing Drum Tower Hospital Clinical Medical College of Traditional Chinese and Western Medicine Nanjing University of Chinese Medicine Nanjing China
Abstract
Oncolytic bacterial therapy has huge application potential for cancer treatment due to its tumor‐targeting capabilities and immune microenvironment activation. However, the severe adverse effects of oncolytic bacteria limit their clinical applications. Enhancing biosafety while maintaining the efficacy of oncolytic bacteria is essential for advancing the clinical translation of live microbial cancer therapies. Here, we construct a mesenchymal stromal cell (MSC)‐mediated tumor‐targeted delivery system for Salmonella typhimurium VNP20009 (MSC‐VNP), which significantly enhances the intertumoral enrichment and safety of VNP. This benefit arises from the tumor‐homing chemotaxis of MSCs and the delayed release of intracellular VNP. To improve the therapeutic effect, we construct engineered MSCs that sustainably secrete PD‐1 nanobodies (MSC‐PD1nb) to treat melanoma in combination with MSC‐VNP. This combination therapy improves antitumor efficacy in a mouse melanoma model by increasing antitumor effector cells (CD8 + T effector cells) and reducing protumor effector cells (CD4 + T regulatory cells). These data indicate that MSC‐mediated combination immunotherapy offers a promising antitumor immune strategy, providing a prospect for expanding the therapeutic application of oncolytic bacteria in cancer.
Related
- Immune reprogramming of 3D tumor models via optoporation-mediated targeted gene delivery to macrophages
- Exosome-mediated immunomodulation of osteoarthritic synovitis: macrophage fibroblast crosstalk, targeted delivery, and clinical translation
- MRI-Trackable Mesenchymal Stem Cells for Oncolytic Therapy: A Clinically Feasible Dual-Labeling Protocol
- Oncolytic virus VT1092M synergizes with immune checkpoint inhibitors against intraperitoneal metastases of colorectal cancer
- Oncolytic Newcastle disease virus promotes tumor cell apoptosis through SUMO-1-dependent PRKN-mediated degradation of c-Myc
BibTeX
@article{wang2026mesenchymal,
title = {{Mesenchymal Stromal Cells‐Mediated Tumor‐Targeted Delivery of Oncolytic Bacteria Combined With Immune Checkpoint Blockade Against Melanoma}},
author = {Yanning Wang and Tianyun Gao and Feifei Huang and Yaping Wang and Mingmei Yang and Congwang Xu and Dong Chen and Shuo Liu and Yuanyuan Xie and Yong Liu and Bin Wang},
journal = {MedComm},
year = {2026},
month = nov,
doi = {10.1002/mco2.71142},
url = {https://doi.org/10.1002/mco2.71142},
note = {CC BY},
}
RIS
TY - JOUR
TI - Mesenchymal Stromal Cells‐Mediated Tumor‐Targeted Delivery of Oncolytic Bacteria Combined With Immune Checkpoint Blockade Against Melanoma
AU - Yanning Wang
AU - Tianyun Gao
AU - Feifei Huang
AU - Yaping Wang
AU - Mingmei Yang
AU - Congwang Xu
AU - Dong Chen
AU - Shuo Liu
AU - Yuanyuan Xie
AU - Yong Liu
AU - Bin Wang
PY - 2026
DA - 2026/11/16
JO - MedComm
DO - 10.1002/mco2.71142
UR - https://doi.org/10.1002/mco2.71142
AB - Oncolytic bacterial therapy has huge application potential for cancer treatment due to its tumor‐targeting capabilities and immune microenvironment activation. However, the severe adverse effects of oncolytic bacteria limit their clinical applications. Enhancing biosafety while maintaining the efficacy of oncolytic bacteria is essential for advancing the clinical translation of live microbial cancer therapies. Here, we construct a mesenchymal stromal cell (MSC)‐mediated tumor‐targeted delivery system for Salmonella typhimurium VNP20009 (MSC‐VNP), which significantly enhances the intertumoral enrichment and safety of VNP. This benefit arises from the tumor‐homing chemotaxis of MSCs and the delayed release of intracellular VNP. To improve the therapeutic effect, we construct engineered MSCs that sustainably secrete PD‐1 nanobodies (MSC‐PD1nb) to treat melanoma in combination with MSC‐VNP. This combination therapy improves antitumor efficacy in a mouse melanoma model by increasing antitumor effector cells (CD8 + T effector cells) and reducing protumor effector cells (CD4 + T regulatory cells). These data indicate that MSC‐mediated combination immunotherapy offers a promising antitumor immune strategy, providing a prospect for expanding the therapeutic application of oncolytic bacteria in cancer.
SN - 2688-2663
ER -